Naibec files patent for blood-brain barrier permeable delivery system... "Applicable to mRNA and other gene drugs"

[Asia Economy Reporter Hyunseok Yoo] Naivec, a peptide fusion bio-specialized company, announced on the 26th that it has completed a domestic patent application for its self-developed highly effective blood-brain barrier (BBB) permeable delivery system, ‘NIPEP-TPP-BBB Shuttle (BBB Shuttle)’.

Starting with this patent application, Naivec plans to actively enter major overseas markets through a PCT application. The PCT application allows a single international filing to have the effect of direct applications in 153 countries that are members of the PCT. Due to the accumulated data and clearly identified mechanisms, technical discussions with global pharmaceutical companies, including Daiichi Sankyo, are also underway in earnest.

Naivec’s ‘BBB Shuttle’ is designed to be applied to various brain diseases using its proprietary drug delivery platform with targeting functionality, ‘NIPEP-TPP’. It can be applied not only to commonly used antibody drugs but also to gene drugs such as siRNA and mRNA, as well as proteins.

While conducting discussions with global pharmaceutical companies, Naivec has continued research on the BBB Shuttle combined with gene drugs like siRNA, accumulating various data. Research results showed that combining gene siRNA with the targeting-enabled BBB Shuttle significantly suppresses the expression of specific proteins, and stability tests for the siRNA conjugate have already been completed.

A Naivec representative stated, “The blood-brain barrier (BBB) is a biological barrier that is difficult to penetrate, and a BBB-permeable drug delivery system capable of crossing this barrier is essential for treating brain diseases such as brain tumors and Parkinson’s disease. While the permeability of existing drug delivery platforms under development has been only 3-4%, Naivec has verified a drug permeability rate of 9%, which is 2-3 times higher than existing platforms, and the related mechanism has been clearly identified.”

He added, “Without mechanism elucidation and patent rights, joint research and license-out with global pharmaceutical companies are difficult. We are making our best efforts to achieve results through business partnerships such as joint research and technology transfer with global pharmaceutical companies, using this patent application as a milestone.”